Tumor-Associated Antigen Targeted by Radiolabeled Antibody

"Tumor cell via radiolabeled antibody" refers to the approach of using a monoclonal antibody labeled with a radioactive isotope to target and bind specific antigens expressed on the surface of tumor cells. This methodology enables selective delivery of cytotoxic radiation for imaging or therapy, known as radioimmunotherapy, and is especially established for hematologic malignancies (e.g., non-Hodgkin lymphoma) but also explored for solid tumors. The specific molecular target varies according to the antibody used (e.g., CD20, HER2, CEA); therefore, "tumor cell" is not a single molecular entity but may refer to many different molecular targets recognized as tumor-associated antigens. The main challenge and limitation are the heterogeneity of antigen expression and balancing efficacy with toxicity due to off-target radiation delivery.

Direct delivery of cytotoxic radiation to tumor cells by antibody-mediated targeting of antigens\nMay trigger immune effector functions, but primary therapeutic effect is radiation-induced DNA damage and cell death